KK体育
EN
中文
EN
About Us
About Us
Overview
History
Honor
KK体育:Contact Us
Continuous innovation for better life
Founded in 1995, Jiangsu Hansoh Pharmaceutical Group Co., Ltd. is an innovation-driven pharmaceutical company integrating the R&D, manufacturing, and sales of drugs. As a principal subsidiary of Hansoh Pharma (03692.HK), the Company is committed to improving human health through continuous innovation, particularly in the treatment of major diseases including the areas of oncology, infections, the central nervous system, metabolic disorders, and autoimmune disease.
KK体育:Innovation
Innovation
KK体育:Achievements
KK体育:Therapy Areas
KK体育:R&D Platforms
KK体育:R&D Capability
Continuous innovation for better life
Hansoh Pharma, a leading innovation-driven pharmaceutical company in the PRC, is committed to improving human health through unremitting innovation, focusing mainly on such areas as anti-tumor, anti-infectives, CNS diseases, metabolic diseases, autoimmune diseases.
Products
Products
Key Products
Continuous innovation for better life
After more than 20 years of continuous investment in R&D, Jiangsu Hansoh Pharma has marketed 7 innovative drugs and has over 30 innovative drug programs in different clinical stages with over 50 clinical trials in progress, forming a rich pipeline.
KK体育:Manufacturing
Manufacturing
KK体育:Lean Manufacturing
Quality Management
Continuous innovation for better life
Hansoh Pharma has always maintained dynamic consistency with global advanced access levels by continuously designing and building production facilities and production lines in accordance with international advanced standards and by using advanced production equipment.
Marketing Service
Marketing Service
Market Coverage
KK体育:Hengte Pharmacy
Continuous innovation for better life
Under the new normal in the pharmaceutical industry, Jiangsu Hansoh Pharma endeavors to be proactive in the implementation of national policies and the innovation of business structure.
News
News
Press Releases
KK体育:Media Center
Hansoh Pharma updates
Find the latest and most complete information about Hansoh Pharma!
KK体育:Social Responsibility
Social Responsibility
KK体育:Responsible Governance
KK体育:Green Development
Public Charity
Responsibility integrity diligence innovation
Jiangsu Hansoh Pharma always adheres to the core values of responsibility, integrity, diligence, and innovation, serving human health with scientific and technological innovation, and assuming corporate social responsibility with accountable behavior in conducting business.
Careers
Careers
KK体育:Work with Us
Work with us
We welcome talents worldwide to join us with their entrepreneurship and achieve new levels of success in their career!
Search
中文
EN
KK体育: About Us
Back
Overview
History
Honor
KK体育:Contact Us
Innovation
Back
KK体育:Achievements
Therapy Areas
R&D Platforms
R&D Capability
Products
Back
KK体育:Key Products
Manufacturing
Back
KK体育:Lean Manufacturing
KK体育:Quality Management
KK体育:Marketing Service
Back
KK体育:Market Coverage
KK体育:Hengte Pharmacy
News
Back
Press Releases
KK体育:Media Center
Social Responsibility
Back
Responsible Governance
KK体育:Green Development
Public Charity
Careers
Back
Work with Us
KK体育:
Related Links
Press Releases
KK体育:Press Releases
KK体育:Media Center
Home
News
Press Releases
Year
2024
2023
2022
2021
2020
Search
Big News! Hansoh Pharma MSCI ESG Rating Upgraded to AA, Taking Global Lead in Industry
Recently, Morgan Stanley Capital International (MSCI), one of the world’s most reputable ESG rating institutions, released its latest annual environme...
2023.11.17
Hansoh Pharma's CMO, Professor Wu Qiong, Attends 2023 CHSESI
The 15th China Healthcare Summit of Entrepreneurs, Scientists and Investors (CHSESI), hosted by the China Pharmaceutical Enterprises Association, Chin...
2023.11.08
Widely Acclaimed | Study Results on Saint Luolai from Hansoh Pharma Published in eClinicalMedicine From World-Leading Lancet Journals
On October 28, eClinicalMedicine (IF:15.1), from top global medical journal group The Lancet, released its phase III clinical research paper on Saint ...
2023.11.03
GSK enters exclusive license agreement with Hansoh for HS-20089
· Hansoh’s HS-20089 complements GSK’s portfolio of gynaecologic cancer therapies 20 October 2023, London UK，GSK plc (LSE/NYSE: GSK) and Hansoh ...
2023.10.20
Hansoh Pharma's Ameile Patent Wins China Patent Gold Award at the 24th WIPO-CNIPA Awards for Chinese Outstanding Patented Inventions
The 24th WIPO-CNIPA Awards for Chinese Outstanding Patented Inventions was held in Dalian in Northeast China on October 14. Hansoh Pharma's Ameile pat...
2023.10.18
Driving Growth and Innovation｜Hansoh Pharma Maintains Position in Top Tier of "Top 100 Chinese Innovative Pharmaceutical Companies"
Recently, well-respected industry media “Healthcare Executive Magazine” published the list of the 2023 "Top 100 Chinese Innovative Pharmaceutical Comp...
2023.10.13
Hansoh Pharma Once Again Proves Itself Worthy of "HRoot Outstanding Employer" Honor
Recently Chinese leading human resource media company HRoot announced its "2023 HRoot Awards in Greater China". Hansoh Pharma was once again honored w...
2023.10.08
WCLC 2023 | Hansoh Pharma's AMEILE (Aumolertinib) is to Present 42 Innovative Research at the International Academic Conference
The IASLC 2023 World Conference on Lung Cancer (WCLC) is scheduled to be held in Singapore from September 9 - 12, 2023. During this conference, Hansoh...
2023.08.08
Hansoh Pharma releases key data for Saint Luolai®, introducing a safe and long-lasting innovative drug to CKD patients with renal anemia
Recently, during the 2023 Annual Conference of the Chinese Nephrologist Association (CNA), the "First National Medical Information Publication of Pegm...
2023.08.07
Ameile Patent From Hansoh Pharma Wins China Patent Gold Award
Recently, the China National Intellectual Property Administration issued its Decision on the Awarding of the 24th China Patent Award. The invention pa...
2023.07.29
Hansoh Pharma and SCYNEXIS Announce NMPA Acceptance of the New Drug Application for Ibrexafungerp in China
Shanghai ,July 20, 2023 – Hansoh Pharma(03692.HK）, a leading innovation-driven pharmaceutical company in Greater China, today announced that China’s N...
2023.07.21
Hansoh Pharma and TiumBio Announce Clinical Trial Approval of HS-10518/TU2670’ from NMPA in China
Hansoh Pharmaceutical Group Co., Ltd. (03692.HK), a leading biopharmaceutical company，and TiumBio Co., Ltd. (KOSDAQ: 321550), a clinical-stage biophar...
2023.07.14
KK体育: 1
2
3
KK体育: 4
5
...
10
11
var _hmt = _hmt || []; (function() { var hm = document.createElement("script"); hm.src = "https://hm.baidu.com/hm.js?90c4d9819bca8c9bf01e7898dd269864"; var s = document.getElementsByTagName("script")[0]; s.parentNode.insertBefore(hm, s); })(); !function(p){"use strict";!function(t){var s=window,e=document,i=p,c="".concat("https:"===e.location.protocol?"https://":"http://","sdk.51.la/js-sdk-pro.min.js"),n=e.createElement("script"),r=e.getElementsByTagName("script")[0];n.type="text/javascript",n.setAttribute("charset","UTF-8"),n.async=!0,n.src=c,n.id="LA_COLLECT",i.d=n;var o=function(){s.LA.ids.push(i)};s.LA?s.LA.ids&&o():(s.LA=p,s.LA.ids=[],o()),r.parentNode.insertBefore(n,r)}()}({id:"K9y7fDzSfyJvbjbD",ck:"K9y7fDzSfyJvbjbD"});
k1体育(中国)官方网站app
k1体育·(中国)官方网站-手机APP下载
k1体育·(中国)平台官网
k1体育平台(中国)官网 - ios/安卓/手机版app下载
k1·体育(中国)官方网站-ios/安卓/手机版app下载
EN
